CME article by James W. Jefferson, M.D., Distinguished Senior Scientist, Madison Institute of Medicine, Inc.; Clinical Professor of Psychiatry, University of Wisconsin Medical School; President, Healthcare Technology Systems, Inc.; Co-Director, Lithium and Obsessive-Compulsive Information Centers
Dr. Jefferson has disclosed that he receives grant/research support from Abbott, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Lilly, Novartis, Organon, Janssen, Pfizer, Solvay, and Wyeth-Ayerst; is a consultant for GlaxoSmithKline, Novartis, and TAP; receives honoraria from Bristol-Myers Squibb, Forest, GlaxoSmithKline, Lilly, Novartis, Organon, Pfizer, Solvay, and Wyeth-Ayerst; and is a principal with Healthcare Technology Systems, Inc.
Further, Dr. Jefferson has disclosed that uses of lithium discussed that are not approved by the FDA include preventing or treating clozapine-induced granulocytopenia, immunomodulatory effects, treatment of seborrheic dermatitis, and treatment of oral and genital herpes.
